![Should FDA Have More Say Over Patent Listings in the Orange Book - Lachman Blog](https://www.lachmanconsultants.com/wp-content/uploads/2024/05/Should-FDA-Have-More-Say-Over-Patent-Listings-in-the-Orange-Book-Lachman-Blog.jpg)
Should FDA Have More Say Over Patent Listings in the Orange Book?
This morning, I was reading an article written by Sally Turner in Pharmaceutical Technology (here), suggesting that the FDA take a greater role in the review and validation of the patents that brand-name companies list in the Orange Book (OB). She addresses the Hatch-Waxman Act’s patent listing provisions and discusses other views held on the […]